{"id":"epoetin-alfa-or-epoetin-beta","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-15","effect":"Thrombotic events (DVT, PE, stroke)"},{"rate":"10-20","effect":"Headache"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"<1","effect":"Pure red cell aplasia (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin is a glycoprotein hormone that mimics endogenous erythropoietin, activating the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow. This stimulates proliferation, differentiation, and maturation of red blood cells, increasing hemoglobin levels and oxygen-carrying capacity. It is used to treat anemia in patients with chronic kidney disease, cancer chemotherapy-induced anemia, and other conditions.","oneSentence":"Epoetin alfa/beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:23.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia of chronic kidney disease"},{"name":"Chemotherapy-induced anemia in cancer patients"},{"name":"Anemia in patients with HIV infection on antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06520826","phase":"PHASE3","title":"Vafseo Outcomes In-Center Experience","status":"ACTIVE_NOT_RECRUITING","sponsor":"USRC Kidney Research","startDate":"2024-11-20","conditions":"Anemia of Chronic Kidney Disease","enrollment":2200},{"nctId":"NCT00560404","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":233},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":"Chronic Kidney Disease","enrollment":334},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT03552393","phase":"PHASE2","title":"Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-03","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":40},{"nctId":"NCT00642967","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Anemia","enrollment":127},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT02791763","phase":"PHASE3","title":"Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-06","conditions":"Anaemia","enrollment":355},{"nctId":"NCT02145026","phase":"PHASE4","title":"A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-06","conditions":"Myelodysplastic Syndromes","enrollment":100},{"nctId":"NCT03408639","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-06-22","conditions":"Anemia in End-Stage Renal Disease","enrollment":156},{"nctId":"NCT01975818","phase":"PHASE2","title":"Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":201},{"nctId":"NCT02064426","phase":"PHASE2","title":"Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-13","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":88},{"nctId":"NCT00773513","phase":"PHASE4","title":"A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-12","conditions":"Chronic Renal Anemia","enrollment":2825},{"nctId":"NCT01519947","phase":"PHASE4","title":"A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05-30","conditions":"Anemia, Kidney Disease, Chronic","enrollment":87},{"nctId":"NCT00642304","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03-27","conditions":"Anemia","enrollment":20},{"nctId":"NCT00737464","phase":"PHASE4","title":"A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08-26","conditions":"Anemia","enrollment":132},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT01066000","phase":"PHASE4","title":"A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Anemia","enrollment":33},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT00717366","phase":"PHASE2","title":"Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Renal Anemia","enrollment":64},{"nctId":"NCT00922116","phase":"PHASE4","title":"A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04-30","conditions":"Anemia","enrollment":191},{"nctId":"NCT01342640","phase":"PHASE4","title":"A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-18","conditions":"Anemia","enrollment":70},{"nctId":"NCT00776425","phase":"PHASE4","title":"A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Anemia","enrollment":117},{"nctId":"NCT00737477","phase":"PHASE3","title":"A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09-30","conditions":"Anemia","enrollment":96},{"nctId":"NCT02238080","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Chronic Kidney Diseases","enrollment":197},{"nctId":"NCT01194154","phase":"PHASE2","title":"A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09-30","conditions":"Kidney Disease, Chronic","enrollment":241},{"nctId":"NCT02767765","phase":"PHASE3","title":"A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-06","conditions":"Anemia","enrollment":61},{"nctId":"NCT00394953","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Anemia","enrollment":490},{"nctId":"NCT00077610","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":673},{"nctId":"NCT00364832","phase":"PHASE2","title":"A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-10","conditions":"Anemia","enrollment":137},{"nctId":"NCT01718379","phase":"PHASE2","title":"Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2010-07","conditions":"Myelodysplastic Syndromes","enrollment":132},{"nctId":"NCT02608060","phase":"PHASE4","title":"A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"Anemia","enrollment":4},{"nctId":"NCT01309295","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-11","conditions":"Anemia, Kidney Disease, Chronic","enrollment":250},{"nctId":"NCT02564094","phase":"PHASE4","title":"A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-02","conditions":"Anemia","enrollment":54},{"nctId":"NCT00081484","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":336},{"nctId":"NCT02624141","phase":"PHASE4","title":"A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Anemia","enrollment":10},{"nctId":"NCT00773331","phase":"PHASE3","title":"A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Anemia","enrollment":281},{"nctId":"NCT00559273","phase":"PHASE3","title":"A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Renal Anemia, Chronic","enrollment":307},{"nctId":"NCT00077766","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":313},{"nctId":"NCT00882713","phase":"PHASE3","title":"A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Anemia","enrollment":202},{"nctId":"NCT00605345","phase":"PHASE3","title":"A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Anemia","enrollment":71},{"nctId":"NCT00560547","phase":"PHASE3","title":"A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":""},{"nctId":"NCT00442416","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-02","conditions":"Anemia","enrollment":80},{"nctId":"NCT00327535","phase":"PHASE2","title":"A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Anemia","enrollment":153},{"nctId":"NCT00551291","phase":"PHASE2","title":"A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-08","conditions":"Myelodysplastic Syndromes","enrollment":10},{"nctId":"NCT00827021","phase":"PHASE3","title":"The Clinical Evaluation of the Dose of Erythropoietins Trial","status":"COMPLETED","sponsor":"Giovanni FM Strippoli, MD","startDate":"2009-07","conditions":"Kidney Failure, Chronic","enrollment":656},{"nctId":"NCT02827266","phase":"PHASE3","title":"A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Anemia","enrollment":122},{"nctId":"NCT00545571","phase":"PHASE3","title":"MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":120},{"nctId":"NCT00642850","phase":"PHASE3","title":"STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Anemia","enrollment":188},{"nctId":"NCT01695746","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08","conditions":"Anemia","enrollment":108},{"nctId":"NCT00517881","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Anemia","enrollment":29},{"nctId":"NCT00576303","phase":"PHASE3","title":"A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":200},{"nctId":"NCT00077623","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":572},{"nctId":"NCT00605293","phase":"PHASE3","title":"A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":101},{"nctId":"NCT00517413","phase":"PHASE3","title":"LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":163},{"nctId":"NCT00699348","phase":"PHASE3","title":"A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Anemia","enrollment":351},{"nctId":"NCT00559637","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":184},{"nctId":"NCT00773968","phase":"PHASE3","title":"A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09","conditions":"Anemia","enrollment":140},{"nctId":"NCT00354341","phase":"PHASE3","title":"(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-09","conditions":"Anemia","enrollment":170},{"nctId":"NCT00550680","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Chronic Renal Anemia","enrollment":208},{"nctId":"NCT00413894","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Anemia","enrollment":424},{"nctId":"NCT01156363","phase":"PHASE4","title":"A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10","conditions":"Anemia","enrollment":86},{"nctId":"NCT00262379","phase":"PHASE3","title":"Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2005-12","conditions":"Chronic Hepatitis C","enrollment":229},{"nctId":"NCT02232113","phase":"PHASE4","title":"Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2012-02","conditions":"Anemia, Inflammation, Malnutrition","enrollment":67},{"nctId":"NCT00662220","phase":"PHASE3","title":"High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4","status":"TERMINATED","sponsor":"Foundation for Liver Research","startDate":"2008-04","conditions":"Chronic Hepatitis C","enrollment":110},{"nctId":"NCT00482716","phase":"PHASE3","title":"Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2007-01","conditions":"Anemia, Leukemia, Lymphoma","enrollment":80},{"nctId":"NCT00072059","phase":"PHASE2","title":"Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-07","conditions":"Anemia, Lung Cancer","enrollment":""},{"nctId":"NCT00597584","phase":"PHASE3","title":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-10","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":823},{"nctId":"NCT00434330","phase":"PHASE2","title":"Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2006-12","conditions":"Anemia, Chronic Kidney Disease, Chronic Renal Failure","enrollment":91},{"nctId":"NCT00830609","phase":"PHASE4","title":"High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3","status":"COMPLETED","sponsor":"Dr. Conrado Fernandez","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":101},{"nctId":"NCT01546337","phase":"","title":"Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Rennes University Hospital","startDate":"2008-05","conditions":"Myelodysplastic Syndromes, Anemia, Hemopathies","enrollment":30},{"nctId":"NCT00090753","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Anemia","enrollment":1228},{"nctId":"NCT00442702","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09","conditions":"Anemia","enrollment":228},{"nctId":"NCT00454246","phase":"PHASE3","title":"A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Anemia","enrollment":111},{"nctId":"NCT00654992","phase":"PHASE2, PHASE3","title":"Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2006-09","conditions":"Kidney Failure, Acute","enrollment":71},{"nctId":"NCT00433693","phase":"PHASE3","title":"Correction Study of R744 in Renal Anemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-02","conditions":"Hemodialysis Patients","enrollment":50},{"nctId":"NCT00433615","phase":"PHASE3","title":"Clinical Study of R744 to Predialysis Patients","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-02","conditions":"Anemia in Pre-Dialysis Patients","enrollment":124},{"nctId":"NCT00491868","phase":"PHASE3","title":"Clinical Study of R744 to Hemodialysis Patients","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-06","conditions":"Hemodialysis Patients","enrollment":134},{"nctId":"NCT00492427","phase":"PHASE3","title":"Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-06","conditions":"Predialysis Patients","enrollment":187},{"nctId":"NCT00593801","phase":"NA","title":"Erythropoietin Treatment in Extremely Low Birth Weight Infants","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"1998-05","conditions":"Infant, Low Birth Weight, Anemia","enrollment":219}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2821,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epogen","Neorecormon"],"phase":"phase_3","status":"active","brandName":"Epoetin alfa or Epoetin beta","genericName":"Epoetin alfa or Epoetin beta","companyName":"Affymax","companyId":"affymax","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin alfa/beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia in cancer patients, Anemia in patients with HIV infection on antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}